Valneva to Present at the 17th World Vaccine Congress in Washington D.C. Lyon (France), April 10, 2017 - Valneva SE ("Valneva" or "the Company"), a leading pure play vaccine company, announced today that it will be holding two presentations on Lyme disease and mosquito-transmitted diseases on...Read More
Valneva Announces Signing of a New EB66 (R) Commercial License with Bavarian Nordic Valneva's EB66 (R) cell-line licensed to Bavarian Nordic for MVA-BN (R) based product candidates Valneva to support process development Lyon (France), April 18, 2017 - Valneva SE ("Valneva" or "the Compan...Read More
Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results - confirming financial self-sustainability strategy Total revenues and grants of ?,?29.1 million in Q1 2017 (vs ?,?24.7 million in Q1 2016) driven by...Read More
Valneva to Present at Jefferies 2017 Global Healthcare Conference in New York Lyon (France), June 06, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that Thomas Lingelbach,...Read More